drugset / Trial / NCT01654120

Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

NCT01654120

Phase 4 Completed 37 enrolled Mountain Diabetes and Endocrine Center
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine the effect of adding liraglutide to high dose insulin therapy compared to high dose insulin therapy alone in patients with insulin-treated Type 2 diabetes with insulin requirements of \> 100 units of insulin per day.

Timeline

Start
2011-12
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic Subcutaneous
Subject Liraglutide Peptide 1.8 mg Subcutaneous
Subject insulin aspart Protein / enzyme biologic Subcutaneous
Subject insulin detemir Protein / enzyme biologic Subcutaneous